Rodman & Renshaw Begins Coverage on vTv Therapeutics (NASDAQ:VTVT)

Rodman & Renshaw initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a note issued to investors on Tuesday. The brokerage set a “buy” rating and a $67.00 price target on the biotechnology company’s stock. Rodman & Renshaw’s target price indicates a potential upside of 84.73% from the company’s current price.

A number of other equities research analysts have also recently commented on the company. Zacks Research cut vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Weiss Ratings upgraded vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th. BTIG Research reaffirmed a “buy” rating and issued a $49.00 price target on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Wall Street Zen upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, Evercore initiated coverage on shares of vTv Therapeutics in a research note on Thursday, March 12th. They set an “outperform” rating and a $44.00 price objective on the stock. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, vTv Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $55.33.

vTv Therapeutics Stock Up 3.4%

Shares of VTVT opened at $36.27 on Tuesday. The firm has a market capitalization of $142.90 million, a PE ratio of -39.00 and a beta of 0.27. vTv Therapeutics has a 12-month low of $14.00 and a 12-month high of $44.00. The stock’s fifty day simple moving average is $33.92 and its 200-day simple moving average is $35.66.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 EPS for the quarter, topping the consensus estimate of $0.21 by $1.44. The business had revenue of $36.84 million for the quarter, compared to analyst estimates of $20.00 million. Analysts anticipate that vTv Therapeutics will post -2.19 EPS for the current year.

Institutional Trading of vTv Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. acquired a new stake in vTv Therapeutics in the 4th quarter valued at approximately $221,000. 683 Capital Management LLC bought a new stake in vTv Therapeutics during the 4th quarter worth about $731,000. Geode Capital Management LLC increased its position in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after acquiring an additional 12,896 shares during the last quarter. Finally, Baker BROS. Advisors LP boosted its position in vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after purchasing an additional 51,000 shares during the last quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.